MicroRNAs fine-tune the regulation of Th1/Th17 lymphocyte subsets in multiple sclerosis. We investigated the expression of miRNAs (previously associated with mycobacterial and viral infections) in MS patients and healthy donors (HD) following 6 months natalizumab therapy. In addition, Th1/Th17 cytokines and the presence of anti-EBNA1/VCA IgG in MS patients with different pattern of miRNA expression have been evaluated. MiR-155, miR-26a, miR-132, miR-146a and Th1/Th17 cytokines expression was detected by RT-real time PCR; moreover anti-EBNA1 and VCA IgG titres were measured by ELISA. We observed an up-regulation of miR-155 (p value = 0.009) and miR-132 (p value = 0.04) in MS patients compared to HD. In MS patients, IL-17a (p = 0.037), IFNγ (p = 0.012) and TNFα (p = 0.015) but not IL-6 were over-expressed compared to HD. Two different miRNAs patterns associated to the expression of different cytokines were observed in the MS cohort. Moreover, a down-regulation of miR-155 and miR-26a was seen in MS patients during and after natalizumab therapy. MS patients that over-expressed miR-155 showed a higher EBNA1 IgG titer than MS patients with high levels of miR-26a. In conclusions the expression of particular miRNAs modulates the pro-inflammatory cytokine expression and the humoral response against EBV and this expression is natalizumab regulated.

Natalizumab therapy modulates miR-155, miR-26a and proinflammatory cytokine expression in MS patients / Mameli, Giuseppe; Arru, Giannina; Caggiu, Elisa; Niegowska, Magdalena; Leoni, Stefania; Madeddu, Giordano; Babudieri, Sergio; Sechi, Gianpietro; Sechi, Leonardo Antonio. - In: PLOS ONE. - ISSN 1932-6203. - 11:6(2016), p. e0157153. [10.1371/journal.pone.0157153]

Natalizumab therapy modulates miR-155, miR-26a and proinflammatory cytokine expression in MS patients

MAMELI, Giuseppe;ARRU, Giannina;CAGGIU, Elisa;LEONI, STEFANIA;MADEDDU, Giordano;BABUDIERI, Sergio;SECHI, Gianpietro;SECHI, Leonardo Antonio
2016

Abstract

MicroRNAs fine-tune the regulation of Th1/Th17 lymphocyte subsets in multiple sclerosis. We investigated the expression of miRNAs (previously associated with mycobacterial and viral infections) in MS patients and healthy donors (HD) following 6 months natalizumab therapy. In addition, Th1/Th17 cytokines and the presence of anti-EBNA1/VCA IgG in MS patients with different pattern of miRNA expression have been evaluated. MiR-155, miR-26a, miR-132, miR-146a and Th1/Th17 cytokines expression was detected by RT-real time PCR; moreover anti-EBNA1 and VCA IgG titres were measured by ELISA. We observed an up-regulation of miR-155 (p value = 0.009) and miR-132 (p value = 0.04) in MS patients compared to HD. In MS patients, IL-17a (p = 0.037), IFNγ (p = 0.012) and TNFα (p = 0.015) but not IL-6 were over-expressed compared to HD. Two different miRNAs patterns associated to the expression of different cytokines were observed in the MS cohort. Moreover, a down-regulation of miR-155 and miR-26a was seen in MS patients during and after natalizumab therapy. MS patients that over-expressed miR-155 showed a higher EBNA1 IgG titer than MS patients with high levels of miR-26a. In conclusions the expression of particular miRNAs modulates the pro-inflammatory cytokine expression and the humoral response against EBV and this expression is natalizumab regulated.
Natalizumab therapy modulates miR-155, miR-26a and proinflammatory cytokine expression in MS patients / Mameli, Giuseppe; Arru, Giannina; Caggiu, Elisa; Niegowska, Magdalena; Leoni, Stefania; Madeddu, Giordano; Babudieri, Sergio; Sechi, Gianpietro; Sechi, Leonardo Antonio. - In: PLOS ONE. - ISSN 1932-6203. - 11:6(2016), p. e0157153. [10.1371/journal.pone.0157153]
File in questo prodotto:
File Dimensione Formato  
journal.pone.0157153.PDF

accesso aperto

Tipologia: Versione editoriale (versione finale pubblicata)
Licenza: Creative commons
Dimensione 1.72 MB
Formato Adobe PDF
1.72 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/162336
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 42
social impact